Science foundation invaluable to Arizona The inclusion of C-Path in the Star’s centennial “100 Days of Science” series is a most welcome honor. What need
Race against a million deaths begins at Tucson’s C-Path When I’ll Have Another won the Kentucky Derby in May, no one talked about the hundreds of millions of dollars each year that
Approval of new drugs slowing Fewer new prescription drugs will get approved in the U.S. this year than the 30 approved in 2011, a ratings agency forecasts, add
Tucson tech: Tucson’s C-Path drug institute looks to boost its future funding Tucson’s Critical Path Institute recently got some good news – and some noteworthy recognition – when the U.S. S
Stakeholders Share Data to Design Better Trials for Neurodegenerative Diseases The Coalition Against Major Diseases is pooling clinical data to build disease and drug models.
Renewed Focus on Tuberculosis Holds Promise for New Treatments FDA approved rifampin for the treatment of tuberculosis (TB) in 1971, the same year Intel Corporation invented the first microproc
Tucson institute plays critical cancer role Re: the April 19 article “Vast study advances breast cancer fight.”
ACRO Testifies Before FDA on Clinical Trial Modernization WASHINGTON–(BUSINESS WIRE)– The Association of Clinical Research Organizations (ACRO) today provided the FDA with a nu
C-Path Initiative’s Work on Personalized Medicine Starts to Get Results The Critical path Institute (C-Path), the US Food and Drug Administration (FDA)-supported public-private initiative working to adv